NexPoint Strategic Opportunities Fund
Change company Symbol lookup
Select an option...
NHF NexPoint Strategic Opportunities Fund
FUAPF Global Cannabis Applications Corp
GXG Global X MSCI Colombia ETF
ATMR Altimar Acquisition Corp II
AMD Advanced Micro Devices Inc
BC-A BRUNSWICK 6 500 SENIOR NTS
WST West Pharmaceutical Services Inc
ITT ITT Inc
PLBY Plby Group Inc
SVFA SVF Investment Corp
Go

Company profile

NexPoint Strategic Opportunities Fund (the Trust), formerly NexPoint Credit Strategies Fund, is a non-diversified, closed-end management investment company. The Trust's objective is to provide both current income and capital appreciation. The Trust allocates its investments in public equities, private equity investments, collateralized loan obligation (CLOs) debt, high yield bonds, syndicated floating rate bank loans, real estate assets, CLO equity, non-traditional yield oriented investments and hedge exposure where necessary. The Trust invests in various sectors, which include chemicals, energy, gaming and leisure, housing, media and telecommunications, real estate investment trust, healthcare, asset-backed securities, and information technology. NexPoint Advisers L.P. serves as the investment adviser to the Trust.

Closing Price
$14.22
Day's Change
-0.17 (-1.18%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.44
Day's Low
14.09
Volume
(Heavy Day)
Volume:
204,321

10-day average volume:
81,203
204,321

Government health officials tell White House to scale back booster plan: report

2:48 pm ET September 3, 2021 (MarketWatch)
Print

Government health officials have advised the White House to scale back President Joe Biden's promise to offer boosters to vaccinated Americans beginning later this month, because available data are insufficient to determine they are necessary, the New York Times reported Friday, citing unnamed people described as familiar with the discussion. Dr. Janet Woodcock, the acting commissioner of the Food and Drug Administration, and Dr. Rochelle P. Walensky, director of the Centers for Disease Control and Prevention, told the White House that they will only be able to determine in the coming weeks whether boosters are necessary for people who received the vaccine developed by Pfizer Inc. (PFE) and German partner BioNTech SE (BNTX), and, even then, they may only be needed by certain individuals. Biden said the government would only act with the approval of the FDA. But health experts were concerned that the Biden government was getting ahead of itself and ahead of its own regulatory agencies. The FDA is also awaiting data from Israel, which is already administering boosters to people 12 and older amid concerns that the vaccine's potency wanes over time. The FDA wants to see the underlying data on which that decision was based.

-Ciara Linnane

	

(END) Dow Jones Newswires

September 03, 2021 14:48 ET (18:48 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.